clinical trial · NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative NeoplasmsINCA036978Standard disease-directed therapy
brief summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
started
Apr 27, 2026
primary completion
May 24, 2030
completion
May 24, 2030
last updated
Apr 15, 2026
official title
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol